Literature DB >> 33253355

Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.

Katayoun Ayasoufi1, Christian K Pfaller2,3, Laura Evgin2, Roman H Khadka1,4, Zachariah P Tritz1,4, Emma N Goddery1,4, Cori E Fain1,4, Lila T Yokanovich1,4, Benjamin T Himes1,5, Fang Jin1, Jiaying Zheng2,4, Matthew R Schuelke1,2,4,6, Michael J Hansen1, Wesley Tung1, Ian F Parney1,5, Larry R Pease1, Richard G Vile1,2, Aaron J Johnson1,2,7.   

Abstract

Immunosuppression of unknown aetiology is a hallmark feature of glioblastoma and is characterized by decreased CD4 T-cell counts and downregulation of major histocompatibility complex class II expression on peripheral blood monocytes in patients. This immunosuppression is a critical barrier to the successful development of immunotherapies for glioblastoma. We recapitulated the immunosuppression observed in glioblastoma patients in the C57BL/6 mouse and investigated the aetiology of low CD4 T-cell counts. We determined that thymic involution was a hallmark feature of immunosuppression in three distinct models of brain cancer, including mice harbouring GL261 glioma, B16 melanoma, and in a spontaneous model of diffuse intrinsic pontine glioma. In addition to thymic involution, we determined that tumour growth in the brain induced significant splenic involution, reductions in peripheral T cells, reduced MHC II expression on blood leucocytes, and a modest increase in bone marrow resident CD4 T cells. Using parabiosis we report that thymic involution, declines in peripheral T-cell counts, and reduced major histocompatibility complex class II expression levels were mediated through circulating blood-derived factors. Conversely, T-cell sequestration in the bone marrow was not governed through circulating factors. Serum isolated from glioma-bearing mice potently inhibited proliferation and functions of T cells both in vitro and in vivo. Interestingly, the factor responsible for immunosuppression in serum is non-steroidal and of high molecular weight. Through further analysis of neurological disease models, we determined that the immunosuppression was not unique to cancer itself, but rather occurs in response to brain injury. Non-cancerous acute neurological insults also induced significant thymic involution and rendered serum immunosuppressive. Both thymic involution and serum-derived immunosuppression were reversible upon clearance of brain insults. These findings demonstrate that brain cancers cause multifaceted immunosuppression and pinpoint circulating factors as a target of intervention to restore immunity.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  T cells; glioblastoma; immunosuppression; neuroimmunology; thymus;  

Mesh:

Substances:

Year:  2020        PMID: 33253355      PMCID: PMC7954397          DOI: 10.1093/brain/awaa343

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  70 in total

1.  IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation.

Authors:  C L Mackall; T J Fry; C Bare; P Morgan; A Galbraith; R E Gress
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 2.  The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis.

Authors:  Jeremiah McDole; Aaron J Johnson; Istvan Pirko
Journal:  Neurol Res       Date:  2006-04       Impact factor: 2.448

3.  Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection.

Authors:  Felipe A Pinho-Ribeiro; Buket Baddal; Rianne Haarsma; Maghnus O'Seaghdha; Nicole J Yang; Kimbria J Blake; Makayla Portley; Waldiceu A Verri; James B Dale; Michael R Wessels; Isaac M Chiu
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

4.  GATA-3 promotes T-cell specification by repressing B-cell potential in pro-T cells in mice.

Authors:  Marcos E García-Ojeda; Roel G J Klein Wolterink; Fabrice Lemaître; Odile Richard-Le Goff; Milena Hasan; Rudolf W Hendriks; Ana Cumano; James P Di Santo
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

Review 5.  Cytokines, leptin, and stress-induced thymic atrophy.

Authors:  Amanda L Gruver; Gregory D Sempowski
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

6.  Thymopoiesis in elderly human is associated with systemic inflammatory status.

Authors:  Sara Ferrando-Martínez; Jaime M Franco; Ana Hernandez; Antonio Ordoñez; Encarna Gutierrez; Antonia Abad; Manuel Leal
Journal:  Age (Dordr)       Date:  2009-01-31

7.  Parabiosis in mice: a detailed protocol.

Authors:  Paniz Kamran; Konstantina-Ioanna Sereti; Peng Zhao; Shah R Ali; Irving L Weissman; Reza Ardehali
Journal:  J Vis Exp       Date:  2013-10-06       Impact factor: 1.355

8.  Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.

Authors:  L Zhang; S R Lewin; M Markowitz; H H Lin; E Skulsky; R Karanicolas; Y He; X Jin; S Tuttleton; M Vesanen; H Spiegel; R Kost; J van Lunzen; H J Stellbrink; S Wolinsky; W Borkowsky; P Palumbo; L G Kostrikis; D D Ho
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

9.  Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.

Authors:  Yingyue Zhou; Wilbur M Song; Prabhakar S Andhey; Amanda Swain; Tyler Levy; Kelly R Miller; Pietro L Poliani; Manuela Cominelli; Shikha Grover; Susan Gilfillan; Marina Cella; Tyler K Ulland; Konstantin Zaitsev; Akinori Miyashita; Takeshi Ikeuchi; Makoto Sainouchi; Akiyoshi Kakita; David A Bennett; Julie A Schneider; Michael R Nichols; Sean A Beausoleil; Jason D Ulrich; David M Holtzman; Maxim N Artyomov; Marco Colonna
Journal:  Nat Med       Date:  2020-01-13       Impact factor: 53.440

10.  The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase.

Authors:  Lucas Vicuña; David E Strochlic; Alban Latremoliere; Kiran Kumar Bali; Manuela Simonetti; Dewi Husainie; Sandra Prokosch; Priscilla Riva; Robert S Griffin; Christian Njoo; Stefanie Gehrig; Marcus A Mall; Bernd Arnold; Marshall Devor; Clifford J Woolf; Stephen D Liberles; Michael Costigan; Rohini Kuner
Journal:  Nat Med       Date:  2015-04-27       Impact factor: 53.440

View more
  11 in total

Review 1.  Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.

Authors:  Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad
Journal:  Br J Cancer       Date:  2022-06-04       Impact factor: 9.075

2.  Functional virus-specific memory T cells survey glioblastoma.

Authors:  Jianfang Ning; Noah V Gavil; Shaoping Wu; Sathi Wijeyesinghe; Eyob Weyu; Jun Ma; Ming Li; Florina-Nicoleta Grigore; Sanjay Dhawan; Alexander G J Skorput; Shawn C Musial; Clark C Chen; David Masopust; Pamela C Rosato
Journal:  Cancer Immunol Immunother       Date:  2022-01-10       Impact factor: 6.630

3.  Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome.

Authors:  Balint Otvos; Tyler J Alban; Matthew M Grabowski; Defne Bayik; Erin E Mulkearns-Hubert; Tomas Radivoyevitch; Anja Rabljenovic; Sarah Johnson; Charlie Androjna; Alireza M Mohammadi; Gene H Barnett; Manmeet S Ahluwalia; Michael A Vogelbaum; Peter E Fecci; Justin D Lathia
Journal:  Clin Cancer Res       Date:  2021-02-04       Impact factor: 13.801

4.  A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.

Authors:  Mahdi Abdoli Shadbad; Nima Hemmat; Vahid Khaze Shahgoli; Afshin Derakhshani; Farzad Baradaran; Oronzo Brunetti; Rossella Fasano; Renato Bernardini; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

5.  Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma.

Authors:  Sen Li; Chenyang Zhao; Jinlan Gao; Xinbin Zhuang; Shuang Liu; Xuesha Xing; Qi Liu; Chen Chen; Shusen Wang; Yang Luo
Journal:  J Exp Clin Cancer Res       Date:  2021-08-27

6.  Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma.

Authors:  Qing Yuan; Song-Quan Wang; Guang-Tao Zhang; Jie He; Zhi-Dan Liu; Ming-Rong Wang; Hong-Qing Cai; Jing-Hai Wan
Journal:  Immun Inflamm Dis       Date:  2021-08-27

Review 7.  Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.

Authors:  Vladimir A Ljubimov; Arshia Ramesh; Saya Davani; Moise Danielpour; Joshua J Breunig; Keith L Black
Journal:  Adv Drug Deliv Rev       Date:  2021-11-20       Impact factor: 17.873

Review 8.  Next Steps for Immunotherapy in Glioblastoma.

Authors:  Toni Q Cao; Derek A Wainwright; Catalina Lee-Chang; Jason Miska; Adam M Sonabend; Amy B Heimberger; Rimas V Lukas
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575

9.  Multidimensional modulation of systemic immune by neurosurgical tumor resection in patients with brain tumors.

Authors:  Jia-Wei Wang; Hong-Liang Wang; Qi Liu; Ke Hu; Liujiazi Shao; Jing-Hai Wan
Journal:  Immun Inflamm Dis       Date:  2022-10

Review 10.  Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.

Authors:  Zachariah P Tritz; Katayoun Ayasoufi; Aaron J Johnson
Journal:  Neurooncol Adv       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.